Thrombosis in VEXAS syndrome
Autor: | Xin Rong Lim, Shang Ming Samuel Lee, Thet Mon Oo, Bingwen Eugene Fan, Jie Tian Jeanette Koay, Siew Fen Lee |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Male
Endothelium Deep vein Inflammation Ubiquitin-Activating Enzymes Article Germline mutation Genetics Medicine Humans Platelet Endothelial dysfunction Aged business.industry Thrombosis Hematology Venous Thromboembolism Syndrome medicine.disease Autoinflammatory Syndrome medicine.anatomical_structure Immunology Mutation medicine.symptom Cardiology and Cardiovascular Medicine business VEXAS Syndrome |
Zdroj: | Journal of Thrombosis and Thrombolysis |
ISSN: | 1573-742X 0929-5305 |
Popis: | VEXAS syndrome, an autoinflammatory syndrome due to a Ubiquitin Like Modifier Activating Enzyme 1 (UBA1) somatic mutation, has a high thrombotic burden. We report a case of a 69-year-old male that was diagnosed with VEXAS syndrome who developed venous thromboembolism (VTE). Review of literature of existing VEXAS syndrome cases showed a high thrombotic burden, with the reported incidence of VTE (36.4%) being markedly higher than arterial thrombosis (1.6%), with deep vein thrombosis being more common than pulmonary embolism. Somatic mutation in the UBA1 gene results in decreased ubiquitylation which is a key driver in the development of thrombosis in VEXAS syndrome, due to chronic inflammation and cytokine release from abnormal crosstalk between the intrinsic effector mechanism of innate immune cells, platelets and endothelium resulting in dysregulated haemostasis and endothelial dysfunction. Targeting endothelial dysfunction and reducing inflammatory milieu causing hypercoagulability with immunosuppressants and immunomodulatory agents, together with anticoagulation may be the strategy to prevent recurrent thrombotic events. Supplementary Information The online version contains supplementary material available at 10.1007/s11239-021-02608-y. |
Databáze: | OpenAIRE |
Externí odkaz: |